Skip to Content
Søk Menu

ECCO 2019: Drug survival for biologics differed significantly in Crohn’s disease

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Karina Winther Andersen

Patients’ Gender Roles and Coping Strategies are Important Topics in Health Care Professionals Dialogue with Crohn’s Patients

/ Karina Winther Andersen
CrohnsIBDSeksuell helse Play the Video 5:53
Marc Ferrante

Mirikizumab As a Potential New Treatment in Patients with Crohn’s Disease

/ Marc Ferrante
CrohnsECCO24 Play the Video 8:36
Daniele Noviello

Risankizumab Downregulates IL-23-Induced Mucosal Pathogenic Th17 Cells in Patients with Crohn’s Disease

/ Daniele Noviello
CrohnsECCO24 Play the Video 5:49
Anja Poulsen

Colon Involvement or Isolated Small Intestinal Resection is Associated with a Higher Risk of Re-Resection in Crohn’s Disease Patients

/ Anja Poulsen
CrohnsECCO24 Play the Video 04:49
Joana Revés

No Association Between Bowel Damage and Disability in Patients with Recently Diagnosed Crohn’s Disease

/ Joana Revés
CrohnsECCO24 Play the Video 06:52
Melek-Zahra Sarikaya

Disease Course and Treatment Outcomes of Crohn’s Disease Patients with Early or Late Surgery

/ Melek-Zahra Sarikaya
CrohnsIBD Play the Video 5:41
Manasi Agrawal

ICR versus Anti-TNF Therapy in Crohn’s Disease

/ Manasi Agrawal
CrohnsECCO23 Play the Video 05:09

ECCO 2019: Bone mineral disease is insufficiently evaluated in patients with IBD

/ Bobby Zhao Sheng Lo
ECCO19 Play the Video 4:06

ECCO 2019: Vedolizumab vs anti-TNF in biologic-naive uc-patients

/ Andres Yarur
ECCO19 Play the Video 1:39
Back to top